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(HSCT) patient. The degree of immune suppression appears to be
the most important risk factor for development of serious adeno-
viral disease. While withdrawal of immune suppression, and the
use of cidofovir may have some effect in reducing viral load and
hastening immune recovery, these approaches have appreciable
side effects and are not always effective. Little is known about the
reconstitution of immunity to adenovirus after HSCT. Therefore,
in this current study we have prospectively monitored the recovery
of adenovirus cellular immunity in pediatric HSCT patients re-
ceiving matched-related, mismatched related or unrelated donor
grafts. 23 pediatric HSCT patients (age range 14 months-20 years)
were enrolled on this study which aims to monitor viral load and
recovery of cellular immunity to adenovirus post HSCT. We have
developed and validated a real-time PCR (Q-PCR) to obtain a
quantitative measure of viral load. Q-PCR is more sensitive than
semi-quantitative PCR and shows that adenovirus can be detected
(despite the absence of symptoms) in the blood, stool or urine at
rates of up to 70%. 22 patients have30 days follow-up (mean 147
days, range 60–240 days). 18/22 (81%) have had detectable levels
of adenoviral DNA in stool (14/18) or blood (13/18). Positivity in
the stool usually preceded adenovirus detection in the blood. 3
patients were exclusively positive in the blood on one occasion with
low viral copy number (range 650 to 1200 copies/ml). 8 patients
have had multiple blood samples positive for adenovirus DNA
ranging in peak viral copy concentration from 1200 to 92500 cp/ml
(mean 31056 cp/ml). Peak copy number in the stool ranged from
1  103 to 9  109 cp/gram stool. In a preliminary analysis rising
levels appear to correlate with risk of infection. ELISPOT assay
and tetramer analysis for known HLA-restricted adenovirus
epitopes will be used to monitor recovery of adenovirus speciﬁc
T-cells in these patients. The results from this study will, therefore
provide critical information for our forthcoming clinical trial
where we will evaluate if immunity to adenovirus can be improved
by adoptive transfer of adenovirus speciﬁc CTLs generated by
culture with monocytes transduced with an Ad5/35 adenoviral
vector (Leen et al, Blood 2004;104:2432–40).
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THE EFFECTS OF CYTOTOXIC AND IMMUNOSUPPRESSIVE AGENTS ON
THYMIC RECONSTITUTION
Prockop, S.E.1; O’Reilly, R.J.1; Petrie, H.T.2 1. Memorial Sloan Ket-
tering Cancer Center, New York, NY; 2. University of Miami School of
Medicine, Miami, FL.
One key component of long-term outcome after stem cell trans-
plant (SCT) is successful reconstitution of the immune system. In
this regard, effective reconstitution of antigen-speciﬁc immunity
requires de novo T cell generation. Bone marrow derived progen-
itors seed the thymus and undergo a complex process involving
lineage commitment, proliferation and selection. Coordinated in-
teraction of marrow-derived lymphoid progenitors with thymic
stromal cells is required for successful T lymphopoiesis in the
post-natal thymus. Disruption of the thymic microenvironment
can result in disrupted T cell lymphopoiesis. One cause of pro-
longed defects in generating functional T lymphocytes after SCT
is damage to the thymic microenvironment by radiation or cyto-
toxic therapy. Speciﬁc damage to the thymic microenvironment by
the individual agents used in both myeloablative and non-myeloa-
blative regimens has not been fully evaluated. We have developed
a model system using immunodeﬁcient mice as a platform on
which to assess thymic reconstitution. The thymus of mice deﬁ-
cient for the alpha chain of the IL-7 receptor (IL7R/) can be
reconstituted by the injection of low doses of wild type bone
marrow. The ability to achieve this reconstitution appears to de-
pend on absolute numbers of early intra-thymic precursors, rather
than on total thymic cellularity. Exploiting this model, the ade-
quacy of thymic reconstitution following the administration of
cytotoxic and immunosuppressive agents can be compared to the
thymic reconstitution that occurs in the absence of agents poten-
tially toxic to the thymic stroma. Our model system allows the
evaluation of thymic reconstitution after single agent regimens
insufﬁcient to allow donor cell engraftment in wild type mice. The
effects of several agents on thymic reconstitution will be presented.
In addition we have identiﬁed morphologic consequences of spe-
ciﬁc ablative agents and a phenotype of abnormally developing T
lymphocytes that is speciﬁc to injury from busulfan. It is antici-
pated that this information will lead to strategies to both minimize
delayed immune reconstitution and to augment T cell lymphopoi-
esis post-transplant. In addition, further evaluation of impaired
thymic reconstitution will augment the understanding of lym-
phostromal interactions crucial to normal T cell lymphopoiesis.
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FACTORS UNDERLYING EARLY LYMPHOCYTE RECOVERY AND ASSOCI-
ATED SURVIVAL BENEFIT FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANT FOR LYMPHOPROLIFERATIVE DISORDERS
Hill, J.M.1; Webber, S.M.2; Fitzmaurice, T.F.1; Cole, B.F.2; Szczepi-
orkowski, Z.M.1; Meehan, K.R.1 1. Dartmouth-Hitchcock Medical Cen-
ter, Lebanon, NH; 2. Dartmouth Medical School, Hanover, NH.
Increasing data now exists to substantiate early absolute lympho-
cyte count (ALC) recovery following both allogeneic and autolo-
gous stem cell transplant as a strong prognostic indicator for
survival, particularly with lymphoproliferative disorders (Myeloma
and Lymphoma). Yet, there is still a paucity of insight into speciﬁc
factors affecting the ALC. Furthermore, the level and time of
optimal lymphocyte recovery reported has varied, ranging between
500–1000 cells/mcl at days 15–25 after transplant. Based on the
above, we performed a retrospective analysis of 59 patients with
Myeloma and Lymphoma (HD and NHL) who had undergone
high-dose chemotherapy and autologous stem cell transplant at
Dartmouth-Hitchcock Medical Center during 2002–2004 to assess
potential factors that might correlate with the ALC. For this
analysis, ALC thresholds of 500 on day 15 (ALC-15) and
1000 on day 25 (ALC-25) post-transplant were included, and
correlated with the following four parameters: 1) age; 2) number of
pre-transplant regimens; 3) dose of CD34 cells/kg recipient in-
fused; 4) 	 IL-2 post-transplant. By both univariate and multivar-
iate analysis, no statistically signiﬁcant correlation was found be-
tween the above four parameters and attainment of ALC-15 500
or ALC-25 1000. A trend toward statistical signiﬁcance was
noted for patients receiving 5  106 CD34 cells/kg or for those
receiving post-transplant IL-2. Given the limitations of a retro-
spective analysis, a follow-up prospective assessment of ALC de-
terminants (both clinical and laboratory) during immune reconsti-
tution after transplant is planned. Hopefully, this will help to
clarify optimal transplant conditions for patients with lymphopro-
liferative disorders as well as to elucidate speciﬁc immunologic
events involved in this early lymphocyte recovery that provide the
basis for a post-transplant survival beneﬁt, presumably via im-
proved immune surveillance against infection and minimal residual
disease.
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THYMIC ACTIVITY OF HUMAN GROWTH HORMONE ON MURINE THY-
MOCYTES: POTENTIAL ROLE IN PROMOTING THYMOPOIESIS FOLLOW-
ING BONE MARROW TRANSPLANT
Welniak, L.A.1; Charter, N.S.1; Murphy, W.J.2 1. University of Ne-
vada School of Medicine, Reno, NV; 2. Nevada Cancer Institute, Reno,
NV.
Thus far, very few agents have been demonstrated to positively
affect thymic function. Many cytokines have been shown to pro-
mote peripheral T cell function but only a select few (i.e. IL-7 and
SCF) have been shown to promote thymopoiesis or T progenitor
cell survival. Most cytokines were meant to exert local effects and
it is often difﬁcult to generate the levels needed after systemic
administration to yield sustained biological effects. Hormones, by
their very nature, are well suited for systemic administration. Neu-
roendocrine hormones such as growth hormone (GH) and prolac-
tin (PRL) have long been associated with effects on immune cell
function. We have shown that administration of recombinant hu-
man GH (rhGH) results in the enhanced recovery of thymopoiesis
following murine syngeneic bone marrow transplants. To explore
the mechanism of action, we investigated the effects of GH on
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isolated thymocytes and on thymocyte development in organ cul-
tures. We observed a dose dependent increase in the survival of
isolated day 15 fetal thymocytes. To examine the effect of rhGH in
vitro we ﬁrst developed a serum-free fetal thymic organ culture
assay to eliminate serum as an additional exogenous source of GH
and IGF-1 in the system. In fetal thymic organ cultures performed
in serum-free conditions, the addition of 10–100 ng/ml of rhGH
resulted in signiﬁcant increases in total thymic lobe cellularity,
CD4CD8, and CD4CD8 thymocytes at day 13 of fetal thy-




respectively). In contrast, the addition of 50 ng/ml rhIL-7 results
promotes survival of CD4CD8 thymocytes and exerts a block in
differentiation to CD4CD8 cells in this culture system. These
results demonstrate that promotion of thymopoiesis associated
with rhGH administration after bone marrow transplant may be
due, at least in part, by direct action of rhGH on the thymus and
thymocytes and that mechanism of action appears to differ from
IL-7.
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DEVELOPMENT OF B LYMPHOPOIESIS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Winkler, J.1; Biller, A.1; Roesler, W.1; Schaefer-Eckart, K.2; Wandt,
H.2; Schwerdtfeger, R.3; Holler, E.4; Winkler, T.H.5; Gramatzki, M.6
1. Division of Hematology/Oncology, University of Erlangen, Erlangen,
Germany; 2. Medical Clinic 5, Nuremberg, Germany; 3. BMT Center,
DKD Wiesbaden, Wiesbaden, Germany; 4. Department of Hematology/
Oncology, University of Regensburg, Regensburg, Germany; 5. Hema-
topoiesis Unit, University of Erlangen, Erlangen, Germany; 6. Division
of Stem Cell and Immunotherapy, 2nd Medical Department, University
of Kiel, Kiel, Germany.
Long term engraftment after stem cell transplantation is depen-
dent on pluripotent hematopoietic stem cells capable to multilin-
eage reconstitution. The engraftment and prolonged repopulation
of B lymphoid progenitor cells is dependent on pluripotent hema-
topoietic stem cells. Recently, we could demonstrate that a high
number of B cell progenitors are detectable in the bone marrow
from patients both after allogeneic PBSCT and after allogeneic
BMT. The percentage of CD19CD10 cells pro-B/pre-B cells
showed a high variability and ranged from 0 to 98% of all B
lymphocytes. No statistical difference of precursor B lymphocytes
between BM recipients and PBSC recipients was found. In micro-
satellite analysis, both in PBSC recipients and in BM recipients the
B cell precursors were derived exclusively from the donor. The aim
of the study was to identify predictors of B lymphopoiesis in the
bone marrow after stem cells transplantation. A stepwise, multiple
regression analysis was performed. The stem cell source, BM or
PBSC, the occurrence of GVHD, the conditioning with TBI and
the immunosuppression with ATG were entered as categorical
variables, whereas the BM collection time after transplantation, the
age of the donor and of the recipient, the transplanted stem cell
quantity and the T cell content of the BM sample served as
continuous variables. The time elapsed after transplantation when
BM was collected (p0.002) as well as severe GVHD (aGVHD
grade III/IV or extensive cGVHD) at the time point of sample
analysis (p0.036) were identiﬁed as parameters with an indepen-
dent inﬂuence on the percentage of B cell precursors. The highest
percentage of precursor B cells was found during the ﬁrst year after
transplantation. However, patients with severe GVHD showed the
lowest percentage of precursor B cells. The hyperactive B lympho-
poiesis in the ﬁrst year after transplantation was in contrast to the
low number of circulating B cells. In addition, these studies show,
that G-CSF mobilized PBSC contain sufﬁcient hematopoietic
stem cells capable of long term reconstitution of the B cell com-
partment.
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MAJOR CYTOTOXIC PATHWAYS ARE REQUIRED FOR EFFECTIVE RESIS-
TANCE AGAINST HEMATOPOIETIC ALLOGRAFTS BY EFFECTOR CELLS
DERIVED FROM NAI¨VE BUT NOT MEMORY RECIPIENT T CELLS
Zimmerman, Z.F.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
T cell mediated resistance to engraftment must be prevented
following clinical BMT particularly after T cell depletion and
reduced intensity conditioning. Following sensitization to donor
alloantigen, mice deﬁcient in perforin and FasL (B6-cdd) mount a
vigorous T cell mediated resistance to high numbers of donor BM,
despite the simultaneous blockade/absence of TRAIL, TL1a,
TWEAK, and TNFR1. We are investigating host cytotoxic path-
ways post-BMT to determine if their signiﬁcance differs depend-
ing on whether effector cells are derived from naı¨ve or memory T
cell populations. An ex-vivo model of T effector cell-PC interaction
was developed to address this issue. BM cells were cultured with in
vitro generated effector cells in the presence of SCF, TPO, and
Flt3L for 48 hrs. and then assessed for remaining CFU-GM levels.
Unsensitized B6-wt or B6 cdd spleen/LN cells were stimulated
against H-2d alloantigens. Effector cells from B6-wt or B6-cdd
anti-BALB.B cell lines initiated from antigen sensitized mice were
utilized as a memory-like population. No population inhibited
syngeneic B6 BM CFU activity. BALB/c CFU activity was mark-
edly diminished following incubation with B6-wt effectors but was
not diminished following co-culture with B6-cdd effectors. In
marked contrast, when effector cells from B6-wt and B6-cdd cell
lines were examined, both populations speciﬁcally and profoundly
inhibited BALB.B CFU-GM activity. These latter results are con-
sistent with our ﬁndings reporting strong BMT resistance in situ in
cytotoxically normal and defective sensitized recipients. To begin
addressing the role of cytotoxicity in resistance by effector cells
derived from naı¨ve T cells in vivo, MHC identical C3H.SW BM
was transplanted into cytotoxically normal or defective non-my-
eloablatively (5.5 TBI) conditioned recipients. Preliminary ﬁnd-
ings indicate that “naı¨ve” B6-perforin deﬁcient and B6 CD95L
defective recipients maintain their capacity to rigorously reject
allogeneic BM grafts, however, resistance in B6-cdd mice is weak-
ened. Moreover, failure to reject allogeneic bcl-2 tg BM in non-
donor sensitized recipients supports a requirement for cytotoxic
function by effector T cells derived from naı¨ve T cells. In total,
these data are consistent with the notion that resistance mediated
by effector cells derived from memory—but not naı¨ve—T cells
does not require a contribution by major cell-mediated cytotoxic
pathways.
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EX VIVO GENERATED MYELOID PROGENITORS PROTECT MICE FROM
LETHAL IRRADIATION
Christensen, J.L.; Smith, S.; Gille, D.; Domen, J.; Danenberg, E.;
Wahedi, M.; Fong, T. Cellerant Therapeutics, Palo Alto, CA.
We are investigating the potential application of human myeloid
progenitors (MP) as a novel therapy to enhance immune functions
and provide temporary hematopoietic recovery for victims who are
exposed to life-threatening doses of radiation or high-dose chem-
ical or radio-myeloablation as component of their medical treat-
ment. The myeloid progenitor pool, in both mouse and human
bone marrow, has been characterized using cell surface markers.
Myeloid progenitors include Common Myeloid Progenitors
(CMP), Granulocyte Macrophage Progenitors (GMP) and
Megakaryocyte Erythroid Progenitors (MEP). The CMP and
MEP have been found to provide radioprotection in a syngeneic
mouse model [J Clin Invest. 109:1579–85 (2002)]. We are exam-
ining whether MP also have radioprotective qualities in an alloge-
neic transplantation model. Myeloid progenitors were either
sorted from mouse bone marrow (CD117, CD90.1, Linneg/low
Sca-1) or derived in culture from puriﬁed KTLS mouse HSC
(CD117, CD90.1low, Linneg/low Sca-1). Sorted MPs provide
good radioprotection in the syngeneic and matched unrelated
transplantation settings. While sorted MPs provide only limited
protection in an allogeneic model, progenitors derived ex vivo
protect allogeneic recipients from radiation induced death. The
added burden of opportunistic infection often complicates recov-
ery during periods of neutropenia. MPs have also been shown to
provide protection against otherwise lethal fungal infections in
neutropenic mice [Blood 100:4660–7 (2002)]. We are determining
if cultured derived MP provide protection from both hematopoi-
etic failure and fungal infection. This research is aimed at devel-
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